Counterfeit Alli Update

1/26/2010
The FDA has updated its Public Health Warning about counterfeit Alli (orlistat) 60 mg capsules (120-count refill pack). Additional laboratory tests conducted on counterfeit Alli found that if consumers follow the dosing directions, they may be taking 3 times the usual daily sibutramine dose (twice the recommended maximum dose), which can cause anxiety, nausea, heart palpitations, tachycardia, insomnia, and slight blood pressure increases. Excessive sibutramine amounts are dangerous to people with a history of cardiovascular disease, and can lead to stroke, heart attack, or elevated blood pressure. The FDA recommends that consumers check their current Alli supply to make sure they are not taking counterfeit Alli. If it is suspected that the product is counterfeit, consumers should stop taking the drug and properly dispose of the medication. Consumers should also contact their health care provider if they have taken the counterfeit product and are experiencing more than mild side effects, especially patients with a history of cardiovascular disease.
Clin-eguide™ is an online clinical decision support tool that provides the most accurate evidence-based information for health care providers in the clinical setting. It integrates trusted content from Ovid, Facts & Comparisons®, and Lippincott Williams and Wilkins, as well as other premier publishers.